Targeted Molecular Therapy in Urological Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 253
Special Issue Editor
Special Issue Information
Dear Colleagues,
Molecular targeted therapies are attractive therapeutic approaches in cancer. Both multitargeted and highly selective kinase inhibitors are used to interfere with specific molecules to block cancer growth, progression, and metastasis. Many molecular targeted therapies have been approved by the Food and Drug Administration (FDA) and applied in the treatment of numerous cancer types, especially in urological cancers such as kidney cancer, prostate cancer, and urothelial cancer. Despite the recent understanding and identification of potential biomarkers for novel targeted therapies in urological cancer, there is still a lot of work to be done to make them effective. This Special Issue on "Targeted Molecular Therapy in Urological Cancer" aims to collect original research articles, clinical articles, or literature reviews that provide up-to-date insights to uro-oncologists on better ways to customize cancer treatments.
Prof. Dr. Seetong Pang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
